{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:13:26Z","timestamp":1777936406874,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Subst\ufffdAbuse"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>Here we aimed to characterize clinical outcomes in those receiving treatment at a Veterans Health Administration (VHA) methadone maintenance treatment program (MMT) during the COVID 19 pandemic in which SAMSHA regulations for MMTs were changed to provide a greater number of methadone allotments and decreased clinic-visit frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We report results of a single-site, pre-post cohort study of urine drug screen data 3\u2009months before and after an increase in allotments of take-home medication from the methadone clinic. One hundred twenty-nine patients met inclusion criteria for this study. The study was reviewed by the NYHHS IRB committee and granted final approval by the Research and Development Committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The sample was predominately male, average age 66years and average years in most recent treatment is 4.1\u2009years. No statistical significance was found between period 1 and period 2 in the positive test detection for nonprescribed opiates, methadone and illicit substances ( P\u2009&gt;\u2009.05), number of new medical illnesses or overdoses. We controlled for participant age, substance use disorder diagnosis, psychiatric disorder diagnosis, and number of years in treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion\/Conclusions:<\/jats:title>\n                    <jats:p>The results of the study illustrate the relative safety of the changes made at this particular MMT during the pandemic. Additionally, there was continued adherence to methadone treatment with minimal change in illicit substance use during period 1 and period 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Scientific Significance:<\/jats:title>\n                    <jats:p>To these authors\u2019 knowledge this paper is one of the first to examine clinical outcomes in those with opioid addiction prescribed methadone from MMTs during the COVID 19 pandemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11782218221085590","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T02:15:14Z","timestamp":1650680114000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["COVID 19 and the Opioid Epidemic: An Analysis of Clinical Outcomes During COVID 19"],"prefix":"10.1177","volume":"16","author":[{"given":"Chiemeka","family":"Ezie","sequence":"first","affiliation":[{"name":"Department of Psychiatry, NYU Langone, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Badolato","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Langone, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Rockas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Langone, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayek","family":"Nafiz","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Sands","sequence":"additional","affiliation":[{"name":"VA New York Harbor Healthcare, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Wolkin","sequence":"additional","affiliation":[{"name":"VA New York Harbor Healthcare, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-7159","authenticated-orcid":false,"given":"Pantea","family":"Farahmand","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Langone, New York, NY, USA"},{"name":"VA New York Harbor Healthcare, New York, NY, USA"},{"name":"Bellevue Hospital Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"bibr1-11782218221085590","unstructured":"Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health [press release]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration 2020."},{"key":"bibr2-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"bibr3-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000052"},{"issue":"3","key":"bibr4-11782218221085590","author":"Mattick RP","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr5-11782218221085590","volume":"357","author":"Sordo L","year":"2017","journal-title":"BMJ (Clinical research ed)"},{"key":"bibr6-11782218221085590","unstructured":"Substance Abuse Mental Health Services Administration. FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency. 2020. Accessed May 19, 2020. https:\/\/www.samhsa.gov\/sites\/default\/files\/faqs-for-oud-prescribing-and-dispensing.pdf"},{"key":"bibr7-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa020"},{"key":"bibr8-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2015.1059225"},{"issue":"4","key":"bibr9-11782218221085590","volume":"4","author":"Saulle R","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr10-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.60.6.927"},{"key":"bibr11-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(77)90003-X"},{"key":"bibr12-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.12.002"},{"key":"bibr13-11782218221085590","unstructured":"COVID-19 OTP Guidance and Frequently Asked Questions [press release], 2020."},{"key":"bibr14-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr15-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"bibr16-11782218221085590","volume":"95","author":"Wang QQ","year":"2020","journal-title":"Mol psychiatry"},{"key":"bibr17-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000534"},{"key":"bibr18-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdaa241"},{"key":"bibr19-11782218221085590","doi-asserted-by":"publisher","DOI":"10.1300\/J069v25n01_03"},{"key":"bibr20-11782218221085590","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2015.978675"}],"container-title":["Substance Abuse: Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221085590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11782218221085590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11782218221085590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:30:16Z","timestamp":1777692616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11782218221085590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"alternative-id":["10.1177\/11782218221085590"],"URL":"https:\/\/doi.org\/10.1177\/11782218221085590","relation":{},"ISSN":["1178-2218","1178-2218"],"issn-type":[{"value":"1178-2218","type":"print"},{"value":"1178-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"11782218221085590"}}